CALGARY, June 13, 2018 /CNW/ - Sarus Cannabis Inc. (Sarus) is pleased to announce that it has closed a strategic partnership with Candre Cannabis Inc. (Candre). This partnership strengthens both companies as they work together in the medical cannabis and cannabis derivatives marketplace under the ACMPR (Access to Cannabis for Medical Purposes Regulations).
"I am excited to work closely with the Candre team as we engage in the process of having Sarus become a licensed medical cannabis producer in British Columbia," said Sarus President and CEO Dean Casorso. "We have a strong working relationship with Candre and with our combined strengths will ensure that our entry into the cannabis market is proactive, well researched and thorough."
Sarus has a staged growth strategy with a Phase I project covering approximately 42,000 sq. ft., located near Oliver, British Columbia. Phase II is planned to produce Cannabis from a facility in excess of 100,000 sq. ft., as an extension of the Phase I development.
"Candre is pleased to have Sarus as a partner company and we will continue to move forward toward full-scale production of both our Sundre location and now with Sarus in British Columbia," said Candre President and CEO Jesse Beaudry. "The Candre and Sarus teams will work very hard to achieve a common goal."
As Sarus moves forward on its growth strategy, it will be working with additional investors to secure the capital required for the project phases.
About Sarus Cannabis Inc. Sarus, registered in British Columbia, is in the process of becoming a licensed medical cannabis producer proposing to be based in the Okanagan Valley and will operate under the terms of the ACMPR (Access to Cannabis for Medical Purposes Regulations).
The Sarus team has a strong background in British Columbia and has significant experience in agriculture, regulatory process, operations and business administration to ensure success in the cannabis industry.